Varespladib (LY315920)是一种强效、选择性的group IIA, nonpancreatic secretory PLA2 (sPLA2)抑制剂，IC50值为9nM。
Cas No.:172732-68-2
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Varespladib (LY315920) is a potent and selective inhibitor of group IIA, nonpancreatic secretory PLA2 (sPLA2) with an IC50 value of 9nM [1]. Varespladib acts by binding to the hydrophobic channel of PLA2 toxins and blocking the allosteric activation, which neutralizes the inhibition of prothrombinase by PLA2 toxins[2]. Varespladib has been widely used to delay the symptoms of envenomation and improve survival in a mouse model of lethal snake envenomation [3].
In vitro, Varespladib treatment at 160µM for 12 hours significantly inhibited the Naja atra venom-induced elevation of intracellular reactive oxygen species (ROS) levels and reversed mitochondrial membrane potential damage in NCTC 1469 cells[4]. Varespladib treatment at 10µM for 24h significantly inhibited the mRNA and protein levels of MUC16 in all-trans-retinoic acid (RA)-induced human conjunctival epithelial (HCjE) cells[5]. Preincubation with 26µM Varespladib for 15min significantly inhibited the reduction in twitch amplitude induced by D. siamensis venom and abolished the increase in baseline tension in isolated chicken cervical digastric muscle neuromuscular specimens[6].
In vivo, Varespladib, administered orally at a dose of 50mg/kg daily for 4 weeks, reduced low body weight and abdominal fat, improved gut health and lipid profiles, decreased intestinal inflammation and fibrosis, down-regulated genes involved in immunity and permeability, and suppressed key inflammatory pathways in mice fed a high-fat diet (HFD)[7]. A single dose of Varespladib (4mg/kg) administered via the tail vein for 24 hours reduced levels of rhabdomyolysis and hemolysis markers and ameliorated renal dysfunction in a rat model of wasp sting-induced acute kidney injury[8].
References:
[1] Snyder D W, Bach N J, Dillard R D, et al. Pharmacology of LY315920/S-5920,[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1 H-indol-4-yl] oxy] acetate, a Potent and Selective Secretory Phospholipase A2Inhibitor: A New Class of Anti-Inflammatory Drugs, SPI[J]. The Journal of pharmacology and experimental therapeutics, 1999, 288(3): 1117-1124.
[2] Youngman N J, Walker A, Naude A, et al. Varespladib (LY315920) neutralises phospholipase A2 mediated prothrombinase-inhibition induced by Bitis snake venoms[J]. Comparative Biochemistry and Physiology Part C: Toxicology & Pharmacology, 2020, 236: 108818.
[3] Lewin M, Samuel S, Merkel J, et al. Varespladib (LY315920) appears to be a potent, broad-spectrum, inhibitor of snake venom phospholipase A2 and a possible pre-referral treatment for envenomation[J]. Toxins, 2016, 8(9): 248.
[4] Zhao W, Liu J, Wang S, et al. Varespladib mitigates acute liver injury via suppression of excessive mitophagy on Naja atra envenomed mice by inhibiting PLA2[J]. Toxicon, 2024, 242: 107694.
[5] Hori Y, Spurr-Michaud S J, Russo C L, et al. Effect of retinoic acid on gene expression in human conjunctival epithelium: secretory phospholipase A2 mediates retinoic acid induction of MUC16[J]. Investigative ophthalmology & visual science, 2005, 46(11): 4050-4061.
[6] Lay M, Liang Q, Isbister G K, et al. In vitro efficacy of antivenom and varespladib in neutralising Chinese Russell’s viper (Daboia siamensis) venom toxicity[J]. Toxins, 2023, 15(1): 62.
[7] Shirui M, Yuanyuan L, Linfeng W, et al. Varespladib Alleviates Colonic Inflammation Induced by High‐Fat Diet via Downregulating the TGF‐β/Smad Pathway and AA Pathway by Inhibiting sPLA2[J]. Journal of Gastroenterology and Hepatology, 2025, 40(12): 2933-2943.
[8] Wang R, Gao D, Yu F, et al. Phospholipase A2 inhibitor varespladib prevents wasp sting-induced nephrotoxicity in rats[J]. Toxicon, 2022, 215: 69-76.
Varespladib (LY315920)是一种强效、选择性的group IIA, nonpancreatic secretory PLA2 (sPLA2)抑制剂，IC50值为9nM[1]。Varespladib通过结合PLA2毒素的疏水通道并阻断变构激活来发挥作用，从而中和PLA2毒素对凝血酶原酶的抑制效应[2]。Varespladib已被广泛用于延缓毒蛇咬伤症状并提高致死性蛇咬伤小鼠模型的存活率[3]。
在体外，使用160µM的Varespladib处理12小时，显著抑制了Naja atra诱导的NCTC 1469细胞内活性氧（ROS）水平升高，并逆转了线粒体膜电位损伤[4]。使用10µM的Varespladib处理24小时，显著抑制了全反式维甲酸（RA）诱导的人结膜上皮细胞（HCjE）中MUC16的mRNA和蛋白水平[5]。使用26µM的Varespladib预孵育15分钟，显著抑制了D. siamensis蛇毒诱导的鸡颈二腹肌神经肌肉样本的收缩幅度下降，并消除了基线张力的增加[6]。
在体内，每日口服给予50mg/kg剂量的Varespladib，持续4周，减轻了高脂饮食（HFD）喂养小鼠的低体重和腹部脂肪，改善了肠道健康和血脂谱，降低了肠道炎症和纤维化，下调了参与免疫和通透性的基因，并抑制了关键的炎症通路[7]。通过尾静脉单次给予Varespladib（4mg/kg）24小时，降低了黄蜂蜇伤诱导的急性肾损伤大鼠模型中的横纹肌溶解和溶血标志物水平，并改善了肾功能障碍[8]。
| Cell experiment [1]: | |
|
Cell lines |
Human conjunctival epithelial (HCjE) cells |
|
Preparation Method |
HCjE cells were cultured in Keratinocyte-Serum Free Medium (K-sfm) at 37℃ in the presence of 5% CO2, followed by culture in a 1:1 mixture of K-sfm and low calcium DMEM/F12 to confluence. At confluence, the cells were cultured in DMEM/F12 for 24 hours (baseline control), and then changed to DMEM/F12 with 100nM RA dissolved in DMSO for 24h, along with the treatment of Varespladib (10µM). MUC16 mRNA and protein levels were determined by real-time PCR and Western blot analysis, respectively. |
|
Reaction Conditions |
10µM; 24h |
|
Applications |
Varespladib treatment significantly decreased MUC16 mRNA and protein levels in HCjE cells. |
| Animal experiment [2]: | |
|
Animal models |
Male C57BL/6J mice |
|
Preparation Method |
Male C57BL/6J mice (25±2g; 8-week-old) were housed in a specific pathogen-free (SPF) animal house maintained at 23°C with a 12h light/dark cycle and free access to water and food. The mice were randomly divided into three groups (six mice/group): normal chow diet (NCD), HFD, and HFD + Varespladib (50mg/kg; p.o.). The mice were fed for 4 weeks and sacrificed by cervical dislocation. Body weights were recorded every 2 days. Blood samples were collected for biochemical analyses. |
|
Dosage form |
50mg/kg/day for 4 weeks; p.o. |
|
Applications |
Varespladib treatment reduced body weight and improved blood lipid profiles in in mice fed the HFD. |
|
References: |
|
| Cas No. | 172732-68-2 | SDF | |
| 别名 | 伐瑞拉迪; LY315920 | ||
| 化学名 | 2-(1-benzyl-2-ethyl-3-oxamoylindol-4-yl)oxyacetic acid | ||
| Canonical SMILES | CCC1=C(C2=C(N1CC3=CC=CC=C3)C=CC=C2OCC(=O)O)C(=O)C(=O)N | ||
| 分子式 | C21H20N2O5 | 分子量 | 380.39 |
| 溶解度 | ≥ 8.2 mg/mL in DMSO, ≥ 3.26 mg/mL in EtOH with ultrasonic and warming | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.6289 mL | 13.1444 mL | 26.2888 mL |
| 5 mM | 525.8 μL | 2.6289 mL | 5.2578 mL |
| 10 mM | 262.9 μL | 1.3144 mL | 2.6289 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet